5-HT7 receptor as a potential therapeutic target in irritable bowel syndrome: Current insights and future perspectives.

Irritable bowel syndrome (IBS) affects up to 9% of the population worldwide, but current therapies benefit only 25-30% of patients. Disrupted serotonin (5-HT) signaling alters gut microbiota, permeability and immunity, driving IBS pathogenesis. The serotonin type 7 receptor (5-HT7R), which is widely expressed in both central and peripheral tissues, has emerged as a promising therapeutic target. 5-HT7R regulates peristalsis, modulates dendritic cell morphology and drives anti-inflammatory responses. Furthermore, 5-HT7R antagonists induce analgesia and reduce mucosal innervation. This review summarizes the crucial role of 5-HT7R in the gastrointestinal tract and highlights its potential for future IBS therapy.